OS Therapies (OSTX) Change in Interest Receivables (2023 - 2026)

OS Therapies' (OSTX) quarterly Change in Interest Receivables came in at -$6372.0 in Q1 2026, up 93.26% on a QoQ basis from -$94555.0 in Q3 2024.

OS Therapies (OSTX) Change in Interest Receivables (2023 - 2026) Analysis & Trends

OS Therapies (OSTX) has 3 years of Change in Interest Receivables data on file, last reported at -$6372.0 in Q1 2026.

Quarterly Change in Interest Receivables changed N/A year-over-year to -$6372.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$369952.0 (changed N/A YoY) and the FY2024 annual result came in at -$613605.0, up 23.54% from the prior year.
Change in Interest Receivables improved to -$6372.0 in Q1 2026, from -$94555.0 in the prior quarter.
In the past five years, Change in Interest Receivables ranged from a high of -$6372.0 in Q1 2026 to a low of -$371640.0 in Q3 2023.
A 3-year average of -$177807.0 and a median of -$168269.5 in 2023 frame the typical range for Change in Interest Receivables.
The widest YoY moves for Change in Interest Receivables: up 74.56% in 2024, down 74.97% in 2024.
Tracing OSTX's Change in Interest Receivables over 3 years: stood at -$94300.0 in 2023, then slipped by 0.27% to -$94555.0 in 2024, then jumped by 93.26% to -$6372.0 in 2026.
The last three Change in Interest Receivables figures came in at -$6372.0 (Q1 2026), -$94555.0 (Q3 2024), and -$269025.0 (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Interest Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	OS Therapies	19.46 Mn	19.46 Mn	-	-472.00

Download Data